These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 16218488)

  • 41. [Cardiovascular and gastrointestinal safety of NSAIDs].
    van den Bemt P; Tjwa ET; van Oijen MG
    Ned Tijdschr Geneeskd; 2014; 158():A7311. PubMed ID: 24713339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?
    Nielsen OH; Ainsworth M; Csillag C; Rask-Madsen J
    Aliment Pharmacol Ther; 2006 Jan; 23(1):27-33. PubMed ID: 16393277
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The murky waters of the coxibs: a review of the current state of play.
    Ostor AJ; Hazleman BL
    Inflammopharmacology; 2005; 13(4):371-80. PubMed ID: 16354390
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.
    Patrono C
    Curr Cardiol Rep; 2016 Mar; 18(3):25. PubMed ID: 26841787
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparative study to evaluate the cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients.
    Bhosale UA; Quraishi N; Yegnanarayan R; Devasthale D
    J Basic Clin Physiol Pharmacol; 2015 Jan; 26(1):73-9. PubMed ID: 24620015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
    Bruno A; Tacconelli S; Patrignani P
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Quo vadetis coxibs?].
    Grazio S; Anić B
    Reumatizam; 2005; 52(1):17-27. PubMed ID: 16689107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatotoxicity induced by coxibs: how concerned should we be?
    Bessone F; Hernandez N; Roma MG; Ridruejo E; Mendizabal M; Medina-Cáliz I; Robles-Díaz M; Lucena MI; Andrade RJ
    Expert Opin Drug Saf; 2016 Nov; 15(11):1463-1475. PubMed ID: 27537326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of COX-2 anti-inflammatory drugs on soft tissue healing: a review of the literature.
    Randelli P; Randelli F; Cabitza P; Vaienti L
    J Biol Regul Homeost Agents; 2010; 24(2):107-14. PubMed ID: 20487623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
    Borer JS; Simon LS
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP; Gertler R; Fricker R
    Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Problems of cardiovascular toxicity of coxibs and non-selective NSA].
    Forejtová S
    Vnitr Lek; 2006; 52(7-8):677-85. PubMed ID: 16967608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Coxibs: is there a benefit when compared to traditional non-selective NSAIDs in postoperative pain management?
    Wickerts L; Warrén Stomberg M; Brattwall M; Jakobsson J
    Minerva Anestesiol; 2011 Nov; 77(11):1084-98. PubMed ID: 21617597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
    Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on nonsteriodal anti-inflammatory drugs.
    Ardoin SP; Sundy JS
    Curr Opin Rheumatol; 2006 May; 18(3):221-6. PubMed ID: 16582683
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B; Renner B; Brune K
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Mukherjee D
    Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H; Bombardier C; Davis P; Russell AS;
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Taking stock of coxibs.
    Drug Ther Bull; 2005 Jan; 43(1):1-6. PubMed ID: 15679077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.